Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Sigyn Therapeutics, Inc. (SIGY) had Normalized Income after Taxes of $-1.45M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-1.45M |
|
-- |
|
-- |
|
$0.47M |
|
$-0.47M |
|
$-0.98M |
|
$-1.45M |
|
$-1.45M |
|
$-1.45M |
|
$-1.45M |
|
$-1.45M |
|
|
Normalized Income after Taxes |
$-1.45M |
$-0.47M |
|
$-0.43M |
|
1.61M |
|
1.61M |
|
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$0.00M |
|
-- |
|
$0.05M |
|
$0.05M |
|
$5.49M |
|
-- |
|
-- |
|
$5.49M |
|
$-5.44M |
|
$-5.44M |
|
$-5.44M |
|
1.60M |
|
| Cash Flow Statement Financials | |
$-0.45M |
|
-- |
|
$0.44M |
|
$0.01M |
|
$0.00M |
|
$-0.01M |
|
$0.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.00 |
|
-- |
|
-- |
|
-- |
|
-0.47 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
26.69% |
|
26.69% |
|
-2803.74% |
|
26.69% |
|
$-3.39 |
|
$-0.28 |
|
$-0.28 |
|